Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats

Pain

Volumn 88, Issue 1, 2000, Pages 15-22

  Coudore Civiale, Marie Ange ^a   Courteix, Christine ^a   Fialip, Joseph ^a   Boucher, Michel ^a   Eschalier, Alain ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Allodynia; Cholecystokinin; Diabetic rat; Hyperalgesia; Mononeuropathic rat; Morphine analgesia

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; MORPHINE;

ALLODYNIA; ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; HYPERALGESIA; MALE; MODEL; MONONEUROPATHY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALGESIA; ANALGESICS, OPIOID; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DRUG SYNERGISM; HORMONE ANTAGONISTS; HYPERALGESIA; INDOLES; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; MALE; MEGLUMINE; MORPHINE; NERVOUS SYSTEM DISEASES; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ; TOUCH;

EID: 0034307116     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(00)00304-3     Document Type: Article

References (39)

1. Baber N.S., Dourish C.T., Hill D.R. The role of CCK, caerulein, and CCK antagonists in nociception. Pain. 39:1989;307-328.
2. Bennett G.J., Xie Y-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 33:1988;87-107.
3. Chapman V., Honoré P., Buritova J., Besson J-M. Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-Fos expression in the spinal cord of the rat. Neuroscience. 67:1995;731-739.
4. Courteix C., Eschalier A., Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain. 53:1993;81-88.
5. Courteix C., Bardin M., Chantelauze C., Lavarenne J., Eschalier A. Study of the pharmacological sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain. 57:1994;153-160.
6. Courteix C., Coudoré-Civiale M.A., Eschalier A., Fialip J., Zajac J.M., Lavarenne J. CI988, an antagonist of cholecystokinin type B receptor and 1Dme, an analogue of neuropeptide FF, enhance the analgesic effect of morphine in diabetic rats. Br J Pharmacol. 122:(Suppl):1997;335P.
7. Courteix C., Bourget P., Caussade F., Bardin M., Coudore F., Fialip J., Eschalier A. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics? J Pharmacol Exp Ther. 285:1998;63-70.
8. Courteix C., Coudoré-Civiale M.A., Privat A.M., Zajac J.M., Eschalier A., Fialip J. Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats. Br J Pharmacol. 127:1999;1454-1462.
9. Dickenson A.H. Neurophysiology of opioid poorly responsive pain. Cancer Surveys. 21:1994;5-17.
10. Dourish C.T., O'Neill M.F., Coughlan J., Kitchener S.J., Hawley D., Iversen S.D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol. 176:1990;35-44.
11. Faris P.L. Opiate antagonistic function of cholecystokinin in analgesia and energy balance system. Ann N Y Acad Sci. 448:1985;437-447.
12. Hill D.R., Woodruff G.N. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res. 526:1990;276-283.
13. Hoffmann O., Wiesenfeld-Hallin Z. The CCK-B receptor antagonist CI-988 reverses tolerance to morphine in rats. NeuroReport. 5:1994;2565-2568.
14. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., Woodruff G.N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA. 87:1990;6728-6732.
15. Idänpään-Heikkilä J.J., Perrot S., Guilbaud G., Kayser V. In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics. Eur J Pharmacol. 325:1997;155-164.
16. Kayser V., Guilbaud G. Local and remote modifications of nociceptive sensitivity during carrageenin-induced inflammation in the rat. Pain. 28:1987;99-107.
17. Mao J., Price D.D., Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 62:1995;259-274.
18. Mestre C., Pelissier T., Fialip J., Wilcox G., Eschalier A. A method to perform direct transcutaneous intrathecal injections in rats. J Pharmacol Toxicol Methods. 32:1994;197-200.
19. Moran T., Robinson P., Goldrich M.S., McHugh P. Two brain cholecystokinin receptors: implications for behavioural actions. Brain Res. 362:1986;175-179.
20. B antagonist in rats with nerve ligation injury: role of endogenous enkephalins. Neurosci Lett. 215:1996;161-164.
21. Noble F., Blommaert A., Fournié-Zaluski M.C., Roques B.P. A selective CCKB receptor antagonist potentiates μ-, but not δ-opioid receptor-mediated antinociception in the formalin test. Eur J Pharmacol. 273:1995;145-151.
22. B antagonist in the rat. Neurosci Lett. 181:1994;9-12.
23. Portenoy G.N., Foley K.M., Inturrisi C. The nature of opioid responsiveness and its implication for neuropathic pain; new hypotheses derived from studies of opioid infusions. Pain. 43:1990;273-286.
24. Randall L.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn. 61:1957;409-419.
25. Stanfa L., Dickenson A.H. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br J Pharmacol. 108:1993;967-973.
26. Stanfa L., Dickenson A.H., Xu X.J., Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci. 15:1994;65-66.
27. Tallarida R.J. Statistical analysis of drug combinations for synergism. Pain. 49:1992;93-97.
28. Tasker R.R., DeCarvalho G.T., Dolan E.J. Intractable pain of spinal cord origin: clinical features and implications for surgery. J Neurosurg. 77:1992;373-378.
29. Urban M., Jiang M.C., Gebhart G.F. Participation of central descending nociceptive facilitatory systems in secondary hyperalgesia produced by mustard oil. Brain Res. 737:1996;83-91.
30. Verge V.M.K., Wiesenfeld-Hallin Z., Hökfelt T. Cholecystokinin in mammalian primary sensory neurons and spinal cord: in situ hybridization studies on rat and monkey spinal ganglia. Eur J Neurosci. 5:1993;240-250.
31. Wiesenfeld-Hallin Z., Xu X-J., Hughes J., Horwell D.C., Hökfelt T. PD134308, a selective antagonist of cholecystokinin type-B receptors, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci USA. 87:1990;7105-7109.
32. Willetts J., Urban L., Murase K., Randic M. Actions of cholecystokinin octapeptide on rat spinal dorsal horn neurones. Ann N Y Acad Sci. 448:1985;385-402.
33. Williams R.G., Dimaline R., Varro A., Isetta A.N., Trizio D., Dockray G.J. Cholecystokinin octapeptide in rat central nervous system: immunocytochemical studies using monoclonal antibody that does not react with CGRP. Neurochem Int. 11:1987;433-442.
34. Woolf C.J., Doubell T.P. The pathophysiology of chronic pain-increased sensitivity to low threshold Aβ-fibre inputs. Curr Opin Neurobiol. 4:1994;525-534.
35. B receptors, prevents morphine tolerance in the rat. Br J Pharmacol. 105:1992;591-596.
36. Xu X-J., Puke M.J.C., Verge V.M.K., Wiesenfeld-Hallin Z., Hughes J., Hökfelt T. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain. Neurosci Lett. 152:1993;129-132.
37. Xu X-J., Hao J-X., Seiger A., Hughes J., Hökfelt T., Wiesenfeld-Hallin Z. Chronic pain-related behaviours in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain. 56:1994;271-277.
38. Xu X-J., Hökfelt T., Hughes J., Wiesenfeld-Hallin Z. The CCK-B antagonist CI988 enhances the effect of the reflex-depressive effects of morphine in axotomized rats. NeuroReport. 5:1994;718-720.
39. Zhou Y., Sun Y-H., Zhang Z-W., Han J-S. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCK-B receptor antagonist L-365,260 in rat spinal cord. Eur J Pharmacol. 234:1993;147-154.